Search Results 171-180 of 16656 for alopecia

1. ALPN-202 With PD-1 Inhibition in Advanced Malignancies - Mayo Clinic

   Recovery to Grade ≤ 1 for any non-laboratory toxicity resulting from previous anticancer therapy prior to first dose of ALPN-202 (except alopecia, hearing ...

2. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) - Mayo Clinic

   with the exception for alopecia and vitiligo. Exclusion criteria 6 and 7 are removed with Protocol Amendment 7. 8. Impaired cardiac function or clinically ...

3. Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment - Mayo Clinic

   - Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia ...

4. CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin - Mayo Clinic

   Resolution of treatment-related toxicity to < grade 1; alopecia and cutaneous toxicity are allowed < grade 2; >1 week since palliative RT; Ability to ...

5. Publications - David A. Wetter, M.D. - Mayo Clinic

   Syphilitic alopecia. Intern Med. 2013; 52 (17):2013. View PubMed; Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa ...

6. Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant - Mayo Clinic

   ... alopecia). Patient is currently receiving or has received systemic ... Exception to this criterion: patients with any grade of alopecia are allowed to enter the ...

7. TheraSphere With and Without Durvalumab and Tremelimumab for HCC - Mayo Clinic

   Patients with vitiligo or alopecia 2. Patients with hypothyroidism (e.g. following Hashimoto's syndrome) stable on hormone replacement therapy 3. Any ...

8. Dermatitis - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...

9. 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer - Mayo Clinic

   toxicities related to prior therapies (i.e. prior chemotherapy, radiation, etc.) except alopecia 11. Participants must have adequate organ function: - Bone ...

10. Rochelle R. Torgerson, M.D., Ph.D. - Doctors and Medical Staff - Mayo Clinic

    Advisory Council MemberNational Alopecia Areata Foundation. 2013 - 2016. MemberMedia Expert Team, American Academy of Dermatology. 2013 - 2014. ChairLeadership ...